Compounds > palmitic acid
Page last updated: 2024-10-19

palmitic acid and Non-alcoholic Fatty Liver Disease

palmitic acid has been researched along with Non-alcoholic Fatty Liver Disease in 163 studies

Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.
hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.

Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the potential of GB as a material for the mitigation of NAFLD, we investigated the effects of GB hydrolysates on the hepatic lipid accumulation, inflammation, and endoplasmic reticulum (ER) stress in human hepatoma G2 (Hep G2) cells treated with palmitic acid (PA)."8.12Gryllus bimaculatus De Geer hydrolysates alleviate lipid accumulation, inflammation, and endoplasmic reticulum stress in palmitic acid-treated human hepatoma G2 cells. ( Jeong, Y; Jo, EB; Jung, S; Kim, N; Lee, E; Yoon, S, 2022)
"This study aimed to investigate oxymatrine via regulating miR-182 improved the hepatic lipid accumulation in non-alcoholic fatty liver disease (NAFLD) model."7.96Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease. ( Chen, S; Huang, W; Li, Y; Ren, L; Song, G; Wang, Y; Yang, L; Zhang, H, 2020)
"Non-alcoholic fatty liver (NAFLD) is a widespread disease with various complications including Non-alcoholic steatohepatitis (NASH) that could lead to cirrhosis and ultimately hepatocellular carcinoma (HCC)."5.91Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro. ( El-Derany, MO; El-Mesallamy, HO; Gibriel, AA; Shatta, MA, 2023)
"Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome of hepatic parenchymal cell steatosis caused by excessive lipid deposition, which is the chronic liver disease with the highest incidence in China."5.91Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome. ( Chen, S; Chen, Y; Hou, S; Huang, S; Li, W; Liang, J; Pei, C; Shen, Q; Shi, J; Shi, X, 2023)
" Studies have suggested that platycodin D (PD), one of the main active ingredients in Platycodon grandiflorum, has high bioavailability and significantly mitigates the progress of NAFLD, but the underlying mechanism of this is still unclear."5.72Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model. ( Chen, Y; Chu, R; Fan, J; Li, N; Wang, G; Wang, J; Wen, X; Xing, Y, 2022)
"Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases without effective pharmacological intervention."5.72Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling. ( Jiang, R; Liang, L; Meng, S; Ye, S; Zhou, J; Zhou, X, 2022)
"Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases worldwide."5.72PREX1 depletion ameliorates high-fat diet-induced non-alcoholic fatty liver disease in mice and mitigates palmitic acid-induced hepatocellular injury via suppressing the NF-κB signaling pathway. ( Gong, W; Li, Z; Wang, H; Wang, P; Wu, K; Zou, Y, 2022)
"Nonalcoholic fatty liver disease (NAFLD) is characterized by lipotoxicity and ectopic lipid deposition within hepatocytes."5.62Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis. ( Li, J; Teng, W; Xie, S, 2021)
"Carnosol (CAR) is a kind of diterpenoid with antioxidant, anti-inflammatory and antitumor activities."5.62Carnosol alleviates nonalcoholic fatty liver disease by inhibiting mitochondrial dysfunction and apoptosis through targeting of PRDX3. ( Geng, Y; Hu, Y; Kang, X; Sun, R; Sun, Y; Tian, X; Wang, Y; Wang, Z; Yao, J; Zhao, H; Zhao, Y; Zhu, M, 2021)
"Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease, sometimes ranges from simple steatosis to nonalcoholic steatohepatitis (NASH)."5.56Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes. ( Iida, K; Kishimoto, Y; Kondo, K; Mabashi-Asazuma, H; Sato, A; Tanaka, M, 2020)
"Non-alcoholic fatty liver disease (NAFLD) is excessive fat build-up in the liver without alcohol consumption and includes hepatic inflammation and damage."5.51Sodium fluorocitrate having inhibitory effect on fatty acid uptake ameliorates high fat diet-induced non-alcoholic fatty liver disease in C57BL/6J mice. ( Choi, SE; Cui, R; Han, SJ; Heo, YJ; Hong, SA; Hwang, Y; Jung, IR; Kang, Y; Kim, HJ; Lee, KW; Lee, SJ; Son, Y, 2019)
"Acanthoic acid (AA) is a pimaradiene diterpene isolated from Acanthopanax koreanum Nakai (Araliaceae), with anti-inflammatory and hepatic-protective effects."5.51Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. ( Cui, ZY; Dong, XX; Han, X; Hou, LS; Lian, LH; Nan, JX; Piao, HQ; Song, J; Wang, G; Wu, YL; Zheng, S, 2019)
"However, the role of XBP-1 in NAFLD remains relatively unexplored."5.46Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice. ( Akazawa, Y; Eguchi, S; Kanda, Y; Kido, Y; Matsuda, K; Miyaaki, H; Nakao, K; Nakashima, M; Ohnita, K; Sakai, Y; Tabuchi, M; Takahara, I; Takeshima, F; Taura, N, 2017)
"However, the regulation of HMGB1 in NAFLD, particularly through sirtuin 1 (SIRT1), remains unclear."5.42Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease. ( Gao, D; Gao, L; Hu, Y; Li, Z; Ma, X; Peng, J; Shan, W; Tian, X; Wang, G; Xu, W; Yao, J; Zeng, W; Zhang, N, 2015)
"Non-alcoholic fatty liver disease (NAFLD) is a common disorder characterized by excessive hepatic fat accumulation, production of reactive oxygen species (ROS), inflammation and potentially resulting in non-alcoholic steatohepatitis (NASH), cirrhosis and end-stage liver disease."5.42Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML, 2015)
" In this study, oleic acid/palmitic acid (OA/PA)-induced HepG2 and NCTC 1469 cells were used as non-alcoholic fatty liver disease (NAFLD) cell models, and triacylglycerol (TG) levels were measured by oil red O staining, Nile Red staining, and ELISA."4.31Uncarboxylated Osteocalcin Decreases SCD1 by Activating AMPK to Alleviate Hepatocyte Lipid Accumulation. ( Wang, D; Xu, J; Yang, J; Zhang, M, 2023)
"In primary hepatocytes and AML-12 cells, JM-2 treatment significantly suppressed palmitic acid (PA)-induced JNK activation and PA-induced inflammation and cell apoptosis."4.31A small-molecule JNK inhibitor JM-2 attenuates high-fat diet-induced non-alcoholic fatty liver disease in mice. ( Jin, L; Liang, G; Lou, S; Luo, W; Wang, M; Yang, B; Ye, L; Zhang, Q; Zhang, Y; Zhu, W, 2023)
" In this study, we found, for the first time, that oleic acid/palmitic acid (OA/PA)-induced lipid accumulation was largely abrogated by DDX17 overexpression in both HepG2 (a human hepatocellular carcinoma line) and Hep1-6 (a murine hepatocellular carcinoma line) cells, and this effect was due to a marked reduction in cellular triglyceride (TG) content."4.12DDX17 protects hepatocytes against oleic acid/palmitic acid-induced lipid accumulation. ( An, T; Dou, L; Huang, X; Li, H; Li, J; Man, Y; Shen, T; Tang, W; Zhang, X, 2022)
"To evaluate the potential of GB as a material for the mitigation of NAFLD, we investigated the effects of GB hydrolysates on the hepatic lipid accumulation, inflammation, and endoplasmic reticulum (ER) stress in human hepatoma G2 (Hep G2) cells treated with palmitic acid (PA)."4.12Gryllus bimaculatus De Geer hydrolysates alleviate lipid accumulation, inflammation, and endoplasmic reticulum stress in palmitic acid-treated human hepatoma G2 cells. ( Jeong, Y; Jo, EB; Jung, S; Kim, N; Lee, E; Yoon, S, 2022)
"Recent evidences have linked indole-3-acetic acid (I3A), a gut microbiota-derived metabolite from dietary tryptophan, with the protection against non-alcoholic fatty liver disease (NAFLD)."4.12Indole-3-acetic acid improves the hepatic mitochondrial respiration defects by PGC1a up-regulation. ( Fu, Q; Liu, L; Ma, X; Meng, L; Shao, K; Yan, C; Zhang, C; Zhang, F; Zhang, X; Zhao, X, 2022)
"This study aimed to investigate oxymatrine via regulating miR-182 improved the hepatic lipid accumulation in non-alcoholic fatty liver disease (NAFLD) model."3.96Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease. ( Chen, S; Huang, W; Li, Y; Ren, L; Song, G; Wang, Y; Yang, L; Zhang, H, 2020)
"While the impact of metformin in hepatocytes leads to fatty acid (FA) oxidation and decreased lipogenesis, hepatic microRNAs (miRNAs) have been associated with fat overload and impaired metabolism, contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)."3.96Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes. ( Comas, F; Fernández-Real, JM; Höring, M; Latorre, J; Liebisch, G; Liñares-Pose, L; Lluch, A; López, M; Moreno-Navarrete, JM; Nidhina Haridas, PA; Oliveras-Cañellas, N; Olkkonen, VM; Ortega, FJ; Ricart, W; Zhou, Y, 2020)
"Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%."2.94Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. ( Beals, JW; Chondronikola, M; Field, T; Hellerstein, MK; Klein, S; Nyangau, E; Okunade, AL; Patterson, BW; Schweitzer, GG; Shankaran, M; Sirlin, CB; Smith, GI; Talukdar, S; Yoshino, M, 2020)
"Ceramide plays pathogenic roles in nonalcoholic fatty liver disease (NAFLD) via multiple mechanisms, and as such inhibition of ceramide de novo synthesis in the liver may be of therapeutically beneficial in patients with NAFLD."2.90Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis. ( Fan, JG; Hu, CX; Liu, XL; Pan, Q; Qiao, L; Xin, FZ; Xu, GW; Yang, RX; Zeng, J; Zhang, RN; Zhao, ZH; Zhou, D, 2019)
"We constructed NAFLD model by feeding with high-fat diet for 12 weeks in vivo and Palmitic Acid + Oleic Acid treatment for 24 h in vitro."2.44Erchen decoction alleviates the progression of NAFLD by inhibiting lipid accumulation and iron overload through Caveolin-1 signaling. ( Deng, G; Gao, L; Huang, M; Li, J; Li, Y; Liao, Y; Liu, B; Liu, C; Qin, M; Shi, H; Wang, Y; Wu, C; Xu, Y; Yang, J; Yang, M; Zhang, Y; Zhao, J; Zhou, C, 2024)
"Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome of hepatic parenchymal cell steatosis caused by excessive lipid deposition, which is the chronic liver disease with the highest incidence in China."1.91Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome. ( Chen, S; Chen, Y; Hou, S; Huang, S; Li, W; Liang, J; Pei, C; Shen, Q; Shi, J; Shi, X, 2023)
"Obesity is a major contributing factor for metabolic-associated fatty liver disease (MAFLD)."1.91FGF1 ameliorates obesity-associated hepatic steatosis by reversing IGFBP2 hypermethylation. ( Chen, C; Gao, D; Li, X; Wang, J; Yang, L; Yang, W; Yu, C; Zhang, F; Zhang, JS, 2023)
"Non-alcoholic fatty liver (NAFLD) is a widespread disease with various complications including Non-alcoholic steatohepatitis (NASH) that could lead to cirrhosis and ultimately hepatocellular carcinoma (HCC)."1.91Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro. ( El-Derany, MO; El-Mesallamy, HO; Gibriel, AA; Shatta, MA, 2023)
"DHM targeted 14 potential genes in NAFLD."1.91A network pharmacology-based approach to explore the effect of dihydromyricetin on non-alcoholic fatty liver rats via regulating PPARG and CASP3. ( Li, X; Liu, L; Sun, S, 2023)
"Non-alcoholic fatty liver disease (NAFLD) is the primary chronic liver disease worldwide, mainly manifested by hepatic steatosis."1.91The Different Mechanisms of Lipid Accumulation in Hepatocytes Induced by Oleic Acid/Palmitic Acid and High-Fat Diet. ( Bai, X; Chen, L; Chen, Z; Dong, K; Du, Q; Wang, D; Xu, J; Yang, J; Zhang, M, 2023)
"Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of lipids within hepatocytes, which compromises liver functionality following mitochondrial dysfunction and increased production of reactive oxygen species (ROS)."1.91(+)-Lipoic Acid Reduces Lipotoxicity and Regulates Mitochondrial Homeostasis and Energy Balance in an In Vitro Model of Liver Steatosis. ( Aguennouz, M; Alanazi, AM; Amorini, AM; Barbagallo, IA; Distefano, A; Giallongo, S; Lazzarino, G; Longhitano, L; Macaione, V; Nicolosi, A; Orlando, L; Salomone, F; Saoca, C; Tibullo, D; Tropea, E; Volti, GL, 2023)
"Palmitic acid (PA) is a type of fatty acid that increases and leads to liver apoptosis in MAFLD."1.91PKC-δ-dependent mitochondrial ROS attenuation is involved as 9-OAHSA combats lipoapotosis in rat hepatocytes induced by palmitic acid and in Syrian hamsters induced by high-fat high-cholesterol high-fructose diet. ( Huang, CY; Kuo, WW; Lin, PY; Lin, SZ; Loh, CH; Shih, CY; Situmorang, JH, 2023)
" Studies have suggested that platycodin D (PD), one of the main active ingredients in Platycodon grandiflorum, has high bioavailability and significantly mitigates the progress of NAFLD, but the underlying mechanism of this is still unclear."1.72Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model. ( Chen, Y; Chu, R; Fan, J; Li, N; Wang, G; Wang, J; Wen, X; Xing, Y, 2022)
"Non-alcoholic fatty liver (NAFLD) is a complex metabolic disease characterized by fatty degeneration of hepatocytes."1.72CircLDLR acts as a sponge for miR-667-5p to regulate SIRT1 expression in non-alcoholic fatty liver disease. ( He, Y; Li, Y; Wang, C; Wen, S; Xu, C; Yuan, X; Zhou, L, 2022)
"Auranofin reduced liver fibrosis and lipid accumulation in NASH model mice fed on a Western diet."1.72Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways. ( Jun, DW; Kang, HT; Kim, HS; Koh, DH; Lee, SM; Oh, JH; Roh, YJ, 2022)
"Nonalcoholic fatty liver disease (NAFLD) is a chronic inflammatory disease in which nucleotide-binding domain of leucine-rich repeat protein 3 (NLRP3) inflammasome plays an important role."1.72RNA adenosine deaminase (ADAR1) alleviates high-fat diet-induced nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome. ( Fan, L; Jiang, B; Liu, Y; Wang, F; Xiang, R, 2022)
"Ultrasound was used to estimate NAFLD at admission."1.72Long-chain saturated fatty acids and its interaction with insulin resistance and the risk of nonalcoholic fatty liver disease in type 2 diabetes in Chinese. ( Jiang, LP; Sun, HZ, 2022)
"Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases worldwide."1.72PREX1 depletion ameliorates high-fat diet-induced non-alcoholic fatty liver disease in mice and mitigates palmitic acid-induced hepatocellular injury via suppressing the NF-κB signaling pathway. ( Gong, W; Li, Z; Wang, H; Wang, P; Wu, K; Zou, Y, 2022)
"Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases without effective pharmacological intervention."1.72Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling. ( Jiang, R; Liang, L; Meng, S; Ye, S; Zhou, J; Zhou, X, 2022)
"Lipotoxicity in nonalcoholic fatty liver disease is mediated in part by the activation of the stress kinase JNK, but whether MIF modulates JNK in lipotoxicity is unknown."1.72Exercise inhibits JNK pathway activation and lipotoxicity ( Cui, N; Dun, Y; Li, C; Li, D; Li, H; Liu, S; Liu, Y; Qiu, L; Ripley-Gonzalez, JW; You, B, 2022)
"When fenofibrate was administered to the fatty liver model created via GAN administration and liver steatosis was assessed, a reduction in liver fat deposition was observed, and this model was shown to be useful in drug evaluations involving fatty liver."1.62Establishment of an Adult Medaka Fatty Liver Model by Administration of a Gubra-Amylin-Nonalcoholic Steatohepatitis Diet Containing High Levels of Palmitic Acid and Fructose. ( Fujisawa, K; Kondo, K; Matsumoto, T; Nishimura, Y; Okubo, S; Sakaida, I; Takami, T; Yamada, Y; Yamamoto, N, 2021)
"Carnosol (CAR) is a kind of diterpenoid with antioxidant, anti-inflammatory and antitumor activities."1.62Carnosol alleviates nonalcoholic fatty liver disease by inhibiting mitochondrial dysfunction and apoptosis through targeting of PRDX3. ( Geng, Y; Hu, Y; Kang, X; Sun, R; Sun, Y; Tian, X; Wang, Y; Wang, Z; Yao, J; Zhao, H; Zhao, Y; Zhu, M, 2021)
"Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease characterized by excessive fat accumulation in the liver."1.62Network Pharmacology Exploration Reveals Anti-Apoptosis as a Common Therapeutic Mechanism for Non-Alcoholic Fatty Liver Disease Treated with Blueberry Leaf Polyphenols. ( Chen, HW; Jiang, ZH; Li, Y; Wang, CR; Wong, VK; Zhang, W; Zhou, MY, 2021)
"Non-alcoholic fatty liver disease (NAFLD) is a global clinical problem."1.62Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2. ( Ha, H; Huh, JY; Javaid, HMA; Liang, G; Pak, ES; Sahar, NE; Wang, Y; Zhu, W, 2021)
"IH aggravates NAFLD via RIPK3-dependent necroptosis-modulated Nrf2/NFκB signaling pathway, and which should be considered as a potential therapeutic strategy for the treatment of NAFLD with OSASH."1.62Intermittent hypoxia aggravates non-alcoholic fatty liver disease via RIPK3-dependent necroptosis-modulated Nrf2/NFκB signaling pathway. ( Jiang, W; Liu, H; Liu, L; Wang, L; Yue, S; Zhang, H; Zheng, P; Zhou, L; Zhou, Y, 2021)
"Non-alcoholic fatty liver disease (NAFLD), an emerging risk factor for diabetes, is now recognized as the most common liver disease worldwide."1.62Mesenchymal stem cell-conditioned medium improved mitochondrial function and alleviated inflammation and apoptosis in non-alcoholic fatty liver disease by regulating SIRT1. ( Chen, L; Cui, C; Cui, Y; Guo, X; He, Q; Hu, H; Liang, K; Sha, S; Song, J; Sun, L; Wang, C; Wang, L; Yang, M; Zang, N, 2021)
"Dietary palmitic acid (PA) promotes liver fibrosis in patients with nonalcoholic steatohepatitis (NASH)."1.62The mechanism of increased intestinal palmitic acid absorption and its impact on hepatic stellate cell activation in nonalcoholic steatohepatitis. ( Hanayama, M; Hiasa, Y; Ikeda, Y; Liu, S; Matsuura, B; Mogi, M; Takeshita, E; Utsunomiya, H; Yamamoto, Y; Yoshida, O, 2021)
"Nonalcoholic fatty liver disease (NAFLD) is characterized by lipotoxicity and ectopic lipid deposition within hepatocytes."1.62Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis. ( Li, J; Teng, W; Xie, S, 2021)
" The dosage of 0."1.56Expression of Notch family is altered in non‑alcoholic fatty liver disease. ( Chen, HB; Chen, YW; Ding, WJ; Fan, JG; Qiao, L; Wu, WJ, 2020)
"Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease, sometimes ranges from simple steatosis to nonalcoholic steatohepatitis (NASH)."1.56Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes. ( Iida, K; Kishimoto, Y; Kondo, K; Mabashi-Asazuma, H; Sato, A; Tanaka, M, 2020)
"In the mouse model of NAFLD induced by a high-fat diet, we observed that LRRK2 was decreased in livers."1.56LRRK2 Regulates CPT1A to Promote β-Oxidation in HepG2 Cells. ( Ding, ST; Lin, CW; Lin, YY; Mersmann, HJ; Peng, YJ, 2020)
"The expression level of miR-181a in NAFLD patient serum and a palmitic acid (PA)-induced NAFLD cell model was examined by Q-PCR."1.51Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease. ( Cao, H; Duan, X; Fan, J; Huang, R; Liu, X; Wang, B; Wang, Y, 2019)
"Non-alcoholic fatty liver disease (NAFLD) is excessive fat build-up in the liver without alcohol consumption and includes hepatic inflammation and damage."1.51Sodium fluorocitrate having inhibitory effect on fatty acid uptake ameliorates high fat diet-induced non-alcoholic fatty liver disease in C57BL/6J mice. ( Choi, SE; Cui, R; Han, SJ; Heo, YJ; Hong, SA; Hwang, Y; Jung, IR; Kang, Y; Kim, HJ; Lee, KW; Lee, SJ; Son, Y, 2019)
"Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is characterized by excessive hepatic lipid accumulation."1.51Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells. ( Chen, G; Dong, H; Fang, K; Li, J; Lu, F; Wu, F; Xu, L; Zhao, Y; Zou, X, 2019)
"Acanthoic acid (AA) is a pimaradiene diterpene isolated from Acanthopanax koreanum Nakai (Araliaceae), with anti-inflammatory and hepatic-protective effects."1.51Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. ( Cui, ZY; Dong, XX; Han, X; Hou, LS; Lian, LH; Nan, JX; Piao, HQ; Song, J; Wang, G; Wu, YL; Zheng, S, 2019)
"Non-alcoholic fatty liver disease (NAFLD) has been considered as a multi-factorial metabolic syndrome."1.48Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease. ( Lei, L; Li, L; Yang, X; Zhou, C, 2018)
"Multiple mechanisms are involved in NAFLD, including endoplasmic reticulum stress and oxidative stress."1.48Heat shock protein 70 promotes lipogenesis in HepG2 cells. ( Fan, N; Peng, Y; Zhang, J, 2018)
" Although it is known that SFA or LPS promote hepatic inflammation, a hallmark of NAFLD, it remains unclear how SFA in combination with LPS stimulates host inflammatory response in hepatocytes."1.48Saturated fatty acid combined with lipopolysaccharide stimulates a strong inflammatory response in hepatocytes in vivo and in vitro. ( Huang, Y; Li, Y; Lopes-Virella, MF; Lu, Z; Lyons, TJ; Ru, JH, 2018)
"CQJD ameliorates mouse nonalcoholic steatohepatitis."1.48Cangju Qinggan Jiangzhi Decoction Reduces the Development of NonAlcoholic Steatohepatitis and Activation of Kupffer Cells. ( Chen, J; Chen, T; Cheng, Y; Ping, J, 2018)
"Non-alcoholic fatty liver disease (NAFLD) as a global health problem has clinical manifestations ranging from simple non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), cirrhosis, and cancer."1.48Stable Isotope-Labeled Lipidomics to Unravel the Heterogeneous Development Lipotoxicity. ( Cheng, ML; Ho, HY; Huang, CY; Lynn, KS; Shih, LM; Tang, HY, 2018)
"Finally, a comparisons of in-vitro/NAFLD patient biopsy findings confirmed common gene regulations thus demonstrating clinical relevance."1.48Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease. ( Borlak, J; Breher-Esch, S; Sahini, N; Trincone, A; Wallstab, C, 2018)
"OGT plays an oncogenic role in NAFLD-associated HCC through regulating palmitic acid and inducing ER stress, consequently activating oncogenic JNK/c-jun/AP-1 and NF-κB cascades."1.46O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress. ( Chen, GG; Fu, L; Lai, PB; Liu, D; Liu, K; Wong, N; Wu, JL; Xu, W; Yu, J; Zhang, X, 2017)
"Treatment with Senicapoc decreased palmitic acid-driven HepG2 cell death."1.46Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. ( Duan, B; Goldberg, ID; Hao, YJ; Jiang, K; Jung, D; Li, JS; McCormack, S; Narayan, P; Paka, L; Shi, J; Smith, DE; Yamin, M; Zhou, P, 2017)
"Nonalcoholic fatty liver disease (NAFLD) is currently one of the most common chronic liver diseases, especially in developed countries."1.46The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells. ( Cygal, M; Czajkowska-Bania, K; Dudka, J; Gawrońska-Grzywacz, M; Gieroba, R; Herbet, M; Izdebska, M; Korga, A; Korolczuk, A; Piątkowska-Chmiel, I; Sysa, M, 2017)
"Non-alcoholic fatty liver disease (NAFLD) affects obesity-associated metabolic syndrome, which exhibits hepatic steatosis, insulin insensitivity and glucose intolerance."1.46MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR. ( Cao, Z; Chen, X; Chen, Z; Cui, S; Liu, Q; Nie, H; Ren, T; Song, C; Wang, D; Zhou, Y, 2017)
"Saturated fatty acids (SFA) and their toxic metabolites contribute to hepatocyte lipotoxicity in nonalcoholic steatohepatitis (NASH)."1.46Mixed Lineage Kinase 3 Mediates the Induction of CXCL10 by a STAT1-Dependent Mechanism During Hepatocyte Lipotoxicity. ( Bronk, SF; Freeman, BL; Hirsova, P; Ibrahim, SH; Kabashima, A; Tomita, K, 2017)
"However, the role of XBP-1 in NAFLD remains relatively unexplored."1.46Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice. ( Akazawa, Y; Eguchi, S; Kanda, Y; Kido, Y; Matsuda, K; Miyaaki, H; Nakao, K; Nakashima, M; Ohnita, K; Sakai, Y; Tabuchi, M; Takahara, I; Takeshima, F; Taura, N, 2017)
"Non-alcoholic fatty liver disease (NAFLD) is a chronic disease characterized by accumulation of lipid droplets in hepatocytes."1.43Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis. ( Damiano, F; Gnoni, A; Rochira, A; Siculella, L; Testini, M; Tocci, R, 2016)
"Nonalcoholic fatty liver disease (NAFLD) represents the most common chronic liver disease in industrialized countries."1.43Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications. ( Di Mauro, S; Di Pino, A; Ferro, A; Filippello, A; Piro, S; Pulvirenti, A; Purrello, F; Purrello, M; Rabuazzo, AM; Ragusa, M; Scamporrino, A; Urbano, F, 2016)
"Nonalcoholic fatty liver disease (NAFLD) is accompanied by excessive hepatic lipogenesis via liver X receptor α (LXRα)."1.42PRMT3 regulates hepatic lipogenesis through direct interaction with LXRα. ( Gustafsson, JÅ; Han, HJ; Kim, DI; Lim, JH; Lim, SK; Park, JI; Park, MJ; Park, SH; Yoon, KC, 2015)
"Non-alcoholic fatty liver disease (NAFLD) is a common disorder characterized by excessive hepatic fat accumulation, production of reactive oxygen species (ROS), inflammation and potentially resulting in non-alcoholic steatohepatitis (NASH), cirrhosis and end-stage liver disease."1.42Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML, 2015)
"The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing in parallel with the prevalence of obesity."1.42GADD34-deficient mice develop obesity, nonalcoholic fatty liver disease, hepatic carcinoma and insulin resistance. ( Isobe, K; Nishio, N, 2015)
"In primary human hepatocytes NAFLD relevant factors like inflammatory cytokines, lipopolysaccharide and TGF-β did not affect SR-BI protein."1.42Hepatic scavenger receptor BI is associated with type 2 diabetes but unrelated to human and murine non-alcoholic fatty liver disease. ( Buechler, C; Eisinger, K; Krautbauer, S; Meier, EM; Pohl, R; Rein-Fischboeck, L; Weiss, TS, 2015)
"However, the regulation of HMGB1 in NAFLD, particularly through sirtuin 1 (SIRT1), remains unclear."1.42Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease. ( Gao, D; Gao, L; Hu, Y; Li, Z; Ma, X; Peng, J; Shan, W; Tian, X; Wang, G; Xu, W; Yao, J; Zeng, W; Zhang, N, 2015)
"Non-alcoholic fatty liver disease (NAFLD) is strongly associated with obesity and type 2 diabetes."1.40Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo. ( Choi, IP; Choi, JH; Han, HJ; Kim, DI; Kim, HC; Kim, JC; Lee, JB; Lee, JH; Lim, SK; Park, MJ; Park, SH; Yoon, KC, 2014)
"Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent, chronic liver diseases, worldwide."1.39EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD. ( Alisi, A; Ceccarelli, S; Crudele, A; De Stefanis, C; Gaspari, S; Gnani, D; Locatelli, F; Marquez, VE; Nobili, V; Rota, R; Vella, S, 2013)
"Non-alcoholic fatty liver disease (NAFLD) is commonly associated with obesity, metabolic syndrome and type 2 diabetes."1.38Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes. ( Athias, A; Bouillet, B; Brindisi, MC; Cercueil, JP; Cottet, V; Duvillard, L; Gambert, P; Guiu, B; Habchi, M; Hillon, P; Jooste, V; Petit, JM; Verges, B, 2012)
"Nonalcoholic steatohepatitis (NASH) is associated with obesity and type 2 diabetes, and an increased risk for liver cirrhosis and cancer."1.38Elovl6 promotes nonalcoholic steatohepatitis. ( Atsumi, A; Ishii, K; Kobayashi, K; Kuba, M; Matsumori, R; Matsuzaka, T; Murata, S; Nakagawa, Y; Nakamuta, M; Nie, T; Shimada, M; Shimano, H; Shinozaki, H; Sone, H; Suzuki, H; Suzuki-Kemuriyama, N; Takahashi, A; Takekoshi, K; Yahagi, N; Yamada, N; Yatoh, S, 2012)
"The treatment with palmitic acid produced a significant increase in cell death."1.37Effect of α-linolenic acid on endoplasmic reticulum stress-mediated apoptosis of palmitic acid lipotoxicity in primary rat hepatocytes. ( Bai, J; Dong, L; Shi, H; Yang, X; Zhang, Y, 2011)

Research

Studies (163)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's93 (57.06)24.3611
2020's70 (42.94)2.80

Authors

AuthorsStudies
Zhang, H5
Zhou, L4
Zhou, Y3
Wang, L4
Jiang, W1
Liu, L3
Yue, S1
Zheng, P1
Liu, H2
Fujisawa, K1
Takami, T1
Okubo, S1
Nishimura, Y1
Yamada, Y1
Kondo, K2
Matsumoto, T1
Yamamoto, N1
Sakaida, I1
Geng, Y1
Wang, Y9
Sun, R1
Kang, X1
Zhao, H1
Zhu, M2
Sun, Y1
Hu, Y3
Wang, Z3
Tian, X3
Zhao, Y2
Yao, J3
Wang, CR1
Chen, HW1
Li, Y13
Zhou, MY1
Wong, VK1
Jiang, ZH1
Zhang, W1
Zhu, W2
Sahar, NE1
Javaid, HMA1
Pak, ES1
Liang, G3
Ha, H1
Huh, JY1
Liang, L1
Ye, S1
Jiang, R1
Zhou, X2
Zhou, J3
Meng, S1
Li, J7
Xie, S1
Teng, W1
Lee, J1
Hong, SW1
Kim, MJ1
Moon, SJ1
Kwon, H1
Park, SE1
Rhee, EJ1
Lee, WY1
Zhu, YX1
Zhu, L1
Chen, YF1
Xu, JM1
Shne, ZL1
Liu, RJ1
Zou, J1
Yuan, MQ1
Ye, F1
Zeng, QQ1
Kim, N1
Jung, S1
Lee, E1
Jo, EB1
Yoon, S1
Jeong, Y1
Gindlhuber, J1
Schinagl, M1
Liesinger, L1
Darnhofer, B1
Tomin, T1
Schittmayer, M1
Birner-Gruenberger, R1
Zhang, X6
An, T1
Shen, T1
Li, H2
Dou, L1
Huang, X1
Man, Y1
Tang, W1
Li, Z3
Wu, K1
Zou, Y1
Gong, W1
Wang, P2
Wang, H1
Costabile, G1
Della Pepa, G1
Salamone, D1
Luongo, D1
Naviglio, D1
Brancato, V1
Cavaliere, C1
Salvatore, M1
Cipriano, P1
Vitale, M1
Corrado, A1
Rivellese, AA1
Annuzzi, G1
Bozzetto, L1
Barahona, I1
Rada, P1
Calero-Pérez, S1
Grillo-Risco, R1
Pereira, L1
Soler-Vázquez, MC1
LaIglesia, LM1
Moreno-Aliaga, MJ2
Herrero, L2
Serra, D2
García-Monzon, C2
González-Rodriguez, Á2
Balsinde, J1
García-García, F1
Valdecantos, MP2
Valverde, ÁM3
Xiang, R1
Liu, Y4
Fan, L1
Jiang, B1
Wang, F2
Lee, SM1
Koh, DH1
Jun, DW1
Roh, YJ1
Kang, HT1
Oh, JH1
Kim, HS1
Tao, G1
Zhang, G1
Chen, W2
Yang, C1
Xue, Y1
Song, G3
Qin, S1
Zhang, C1
Fu, Q1
Shao, K1
Ma, X3
Zhang, F3
Meng, L1
Yan, C1
Zhao, X1
Kang, Y2
Song, Y1
Luo, Y1
Song, J3
Li, C2
Yang, S1
Guo, J1
Yu, J2
Cui, N1
Dun, Y1
Ripley-Gonzalez, JW1
You, B1
Li, D1
Qiu, L1
Liu, S2
Frandsen, HS1
Vej-Nielsen, JM1
Smith, LE1
Sun, L3
Mikkelsen, KL1
Thulesen, AP1
Hagensen, CE1
Yang, F1
Rogowska-Wrzesinska, A1
Liu, X5
Hu, M2
Ye, C1
Liao, L1
Ding, C1
Liang, J2
Chen, Y9
Yuan, X3
Wen, S3
Xu, C3
Wang, C4
He, Y5
Shatta, MA2
El-Derany, MO2
Gibriel, AA2
El-Mesallamy, HO2
Wen, X1
Wang, J3
Fan, J2
Chu, R1
Xing, Y1
Li, N1
Wang, G4
Jin, L1
Wang, M1
Yang, B1
Ye, L1
Zhang, Q2
Lou, S1
Zhang, Y7
Luo, W1
Jiang, LP1
Sun, HZ1
Aggarwal, S1
Yadav, V1
Maiwall, R1
Rastogi, A1
Pamecha, V1
Bedi, O1
Maras, JS1
Trehanpati, N1
Ramakrishna, G1
Shen, Q1
Shi, J2
Pei, C1
Chen, S3
Huang, S1
Li, W2
Shi, X1
Hou, S1
Yang, W2
Gao, D2
Yang, L5
Yu, C1
Chen, C2
Li, X4
Zhang, JS1
Wang, D4
Zhang, M2
Xu, J2
Yang, J3
Lu, Z3
Chowdhury, N1
Yu, H2
Syn, WK1
Lopes-Virella, M1
Yilmaz, Ö1
Huang, Y3
Loh, CH1
Kuo, WW1
Lin, SZ1
Shih, CY1
Lin, PY1
Situmorang, JH1
Huang, CY2
Su, S1
Yuan, Y1
Liu, W1
Zheng, Q1
Zeng, X1
Fu, F1
Lu, Y1
Sun, S1
Qi, J2
Yan, X1
Li, L4
Qiu, K1
Huang, W3
Zhou, Z2
Bai, X1
Du, Q1
Chen, L3
Dong, K1
Chen, Z2
Zhang, N3
Liu, T1
Xiao, Y1
Dai, J2
Ma, Z1
Ma, D1
Longhitano, L1
Distefano, A1
Amorini, AM1
Orlando, L1
Giallongo, S1
Tibullo, D1
Lazzarino, G2
Nicolosi, A1
Alanazi, AM1
Saoca, C1
Macaione, V1
Aguennouz, M1
Salomone, F1
Tropea, E1
Barbagallo, IA1
Volti, GL1
Deng, G1
Huang, M1
Shi, H2
Wu, C1
Zhao, J2
Qin, M1
Liu, C2
Yang, M4
Liao, Y1
Zhou, C2
Xu, Y2
Liu, B1
Gao, L3
Liang, C1
Gao, S1
Gao, J1
Li, Q1
Han, X1
Cui, ZY1
Piao, HQ1
Lian, LH1
Hou, LS1
Zheng, S1
Dong, XX1
Nan, JX1
Wu, YL1
Upadhyay, KK1
Jadeja, RN1
Vyas, HS1
Pandya, B1
Joshi, A1
Vohra, A1
Thounaojam, MC1
Martin, PM1
Bartoli, M1
Devkar, RV1
Fang, K1
Wu, F1
Chen, G2
Dong, H1
Xu, L1
Zou, X1
Lu, F1
Li, CX1
Gao, JG1
Wan, XY1
Xu, CF1
Feng, ZM1
Zeng, H1
Lin, YM1
Ma, H1
Xu, P1
Yu, CH1
Li, YM1
Wang, YD1
Li, JY1
Qin, Y1
Liu, Q3
Liao, ZZ1
Xiao, XH1
Yang, RX2
Pan, Q2
Liu, XL2
Zhou, D2
Xin, FZ2
Zhao, ZH2
Zhang, RN2
Zeng, J1
Qiao, L2
Hu, CX1
Xu, GW1
Fan, JG3
Hong, SA1
Jung, IR1
Choi, SE1
Hwang, Y1
Lee, SJ1
Son, Y1
Heo, YJ1
Cui, R1
Han, SJ1
Kim, HJ1
Lee, KW1
Smith, GI1
Shankaran, M1
Yoshino, M1
Schweitzer, GG1
Chondronikola, M1
Beals, JW1
Okunade, AL1
Patterson, BW1
Nyangau, E1
Field, T1
Sirlin, CB1
Talukdar, S1
Hellerstein, MK1
Klein, S1
Latorre, J1
Ortega, FJ1
Liñares-Pose, L1
Moreno-Navarrete, JM1
Lluch, A1
Comas, F1
Oliveras-Cañellas, N1
Ricart, W1
Höring, M1
Liebisch, G2
Nidhina Haridas, PA1
Olkkonen, VM1
López, M1
Fernández-Real, JM1
Cheng, B2
Gao, W1
Wu, X3
Zheng, M1
Yu, Y1
Song, C2
Miao, W1
Yang, Z1
Yang, X3
Gao, Y2
Poulsen, KL1
Sanz-Garcia, C1
Huang, E1
McMullen, MR1
Roychowdhury, S1
Dasarathy, S1
Nagy, LE1
Shen, B1
Feng, H1
Cheng, J1
Jin, M1
Zhao, L4
Wang, Q1
Qin, H1
Liu, G1
Zhao, D1
Wang, X2
Gurley, EC1
Liu, R1
Hylemon, PB1
Zhou, H1
Tanaka, M1
Sato, A1
Kishimoto, Y1
Mabashi-Asazuma, H1
Iida, K1
Ren, L2
Ding, WJ1
Wu, WJ1
Chen, YW1
Chen, HB1
Mittal, S1
Inamdar, S1
Acharya, J1
Pekhale, K1
Kalamkar, S1
Boppana, R1
Ghaskadbi, S1
Yuan, S1
Pan, Y1
Zhang, Z2
Teng, Y1
Liang, H1
Yang, H1
Zhou, P2
Lin, CW1
Peng, YJ1
Lin, YY1
Mersmann, HJ1
Ding, ST1
Vergani, L1
Baldini, F1
Khalil, M1
Voci, A1
Putignano, P1
Miraglia, N1
Gai, H1
Zhou, F1
Ai, J1
Zhan, J1
You, Y1
Wen, F1
Shi, Z1
Tan, Y1
Wei, L2
Zhu, X4
Meng, X1
Ji, W1
Yu, T1
Zheng, E1
Xia, J1
Ding, Q1
Hou, Z1
Ruan, XZ2
Cui, Y1
Cui, C1
Liang, K1
Sha, S1
He, Q1
Hu, H1
Guo, X1
Zang, N1
Ogino, N1
Miyagawa, K1
Nagaoka, K1
Matsuura-Harada, Y1
Ogino, S1
Kusanaga, M1
Oe, S1
Honma, Y1
Harada, M1
Eitoku, M1
Suganuma, N1
Ogino, K1
Frietze, KK1
Brown, AM1
Das, D1
Franks, RG1
Cunningham, JL1
Hayward, M1
Nickels, JT1
Amorim, R1
Simões, ICM1
Veloso, C1
Carvalho, A1
Simões, RF1
Pereira, FB1
Thiel, T1
Normann, A1
Morais, C1
Jurado, AS1
Wieckowski, MR1
Teixeira, J1
Oliveira, PJ1
Campos-Espinosa, A1
Guzmán, C1
Ali, ES1
Girard, D1
Petrovsky, N1
Hanayama, M1
Yamamoto, Y1
Utsunomiya, H1
Yoshida, O1
Mogi, M1
Matsuura, B1
Takeshita, E1
Ikeda, Y1
Hiasa, Y1
Liang, Y1
Tu, J1
Gao, X3
Deng, K1
El-Samahy, MA1
You, P1
Fan, Y1
Lin, C1
Fang, J1
Xiang, Q1
Zhou, R1
Duan, NN1
Liu, XJ1
Wu, J1
Xu, W2
Wu, JL1
Fu, L1
Liu, K2
Liu, D1
Chen, GG1
Lai, PB1
Wong, N1
Santos-Laso, A1
Perugorria, MJ1
Banales, JM1
He, K2
Miao, C1
Wang, T1
Li, P2
Gong, J3
Cai, C2
Li, S2
Bartolini, D1
Torquato, P1
Barola, C1
Russo, A1
Rychlicki, C1
Giusepponi, D1
Bellezza, G1
Sidoni, A1
Galarini, R1
Svegliati-Baroni, G1
Galli, F1
Paka, L1
Smith, DE1
Jung, D1
McCormack, S1
Duan, B1
Li, JS1
Hao, YJ1
Jiang, K1
Yamin, M1
Goldberg, ID1
Narayan, P1
Shen, W3
Izdebska, M1
Piątkowska-Chmiel, I1
Korolczuk, A1
Herbet, M1
Gawrońska-Grzywacz, M1
Gieroba, R1
Sysa, M1
Czajkowska-Bania, K1
Cygal, M1
Korga, A1
Dudka, J1
Hsiao, PJ1
Chiou, HC1
Jiang, HJ1
Lee, MY2
Hsieh, TJ1
Kuo, KK1
Takaki, H1
Akazawa, Y2
Kido, Y2
Morishita, M1
Honda, T1
Shibata, H1
Miuma, S1
Miyaaki, H2
Taura, N2
Kondo, H1
Nakao, K2
Nie, H1
Cui, S1
Ren, T1
Cao, Z1
Chen, X1
Lai, S1
Kuang, Y1
Cui, H1
Yang, Y1
Sun, W1
Chen, D1
Yan, Q1
Wen, L2
Wu, B1
Ge, X1
Ying, S1
Shan, X1
Cao, HX1
Wang, BC1
Xiao, WC1
Zhang, J3
Chen, SL1
Shi, YJ1
Xiao, F1
An, W1
Cheng, C1
Deng, X1
Xu, K1
Lei, L1
Fan, N1
Peng, Y1
Kim, JW1
Choi, SJ1
Lim, CW1
Lee, K1
Kim, B1
Ru, JH1
Lopes-Virella, MF1
Lyons, TJ1
Liu, J1
Yang, P1
Zuo, G1
He, S1
Tan, W1
Su, C1
Ruan, X1
Cheng, Y1
Chen, T1
Ping, J1
Chen, J3
Cansanção, K1
Silva Monteiro, L1
Carvalho Leite, N1
Dávalos, A1
Tavares do Carmo, MDG1
Arantes Ferreira Peres, W1
Shih, LM1
Tang, HY1
Lynn, KS1
Ho, HY1
Cheng, ML1
Guo, S1
Zhang, S2
Liu, A1
Shi, L1
Breher-Esch, S1
Sahini, N1
Trincone, A1
Wallstab, C1
Borlak, J1
Huang, R1
Duan, X1
Cao, H1
Wang, B1
Liao, CY1
Song, MJ1
Mauer, AS2
Revzin, A1
Malhi, H3
Li, T2
Brown, MV1
Compton, SA1
Milburn, MV1
Lawton, KA1
Cheatham, B1
Cao, J2
Feng, XX1
Yao, L2
Ning, B2
Yang, ZX2
Fang, DL1
Vella, S1
Gnani, D1
Crudele, A1
Ceccarelli, S1
De Stefanis, C1
Gaspari, S1
Nobili, V1
Locatelli, F1
Marquez, VE1
Rota, R1
Alisi, A1
Tu, QQ1
Zheng, RY1
Hu, L1
Chang, YX1
Li, MH1
Wang, RY1
Huang, DD1
Wu, MC1
Hu, HP1
Wang, HY1
Pirazzi, C1
Valenti, L1
Motta, BM1
Pingitore, P1
Hedfalk, K1
Mancina, RM1
Burza, MA1
Indiveri, C1
Ferro, Y1
Montalcini, T1
Maglio, C1
Dongiovanni, P1
Fargion, S1
Rametta, R1
Pujia, A1
Andersson, L1
Ghosal, S1
Levin, M1
Wiklund, O1
Iacovino, M1
Borén, J1
Romeo, S1
Mayoral, R1
Agra, N1
Pardo, V2
Miquilena-Colina, ME1
Vargas-Castrillón, J1
Lo Iacono, O1
Corazzari, M1
Fimia, GM1
Piacentini, M1
Muntané, J2
Boscá, L1
Martín-Sanz, P1
Jia, Y1
Suo, L1
Guo, Y1
Yang, G1
Park, MJ2
Kim, DI2
Lim, SK2
Choi, JH1
Kim, JC1
Yoon, KC2
Lee, JB1
Lee, JH3
Han, HJ2
Choi, IP1
Kim, HC1
Park, SH2
Galloway, CA1
Lee, H1
Brookes, PS1
Yoon, Y1
Park, JI1
Gustafsson, JÅ1
Lim, JH1
Miyamoto, Y1
Kumar, S1
Mott, JL1
Xu, R1
Edin, ML1
Zeldin, DC1
Wang, DW1
Lou, J1
Jiang, Y1
Lee, JJ1
Lambert, JE1
Hovhannisyan, Y1
Ramos-Roman, MA1
Trombold, JR1
Wagner, DA1
Parks, EJ1
García-Ruiz, I1
Solís-Muñoz, P1
Fernández-Moreira, D1
Muñoz-Yagüe, T1
Solís-Herruzo, JA1
Seeßle, J1
Schmitz, G1
Stremmel, W1
Chamulitrat, W1
Win, S1
Than, TA1
Le, BH1
García-Ruiz, C2
Fernandez-Checa, JC2
Kaplowitz, N1
Min, HK1
Mirshahi, F1
Verdianelli, A1
Pacana, T1
Patel, V1
Park, CG1
Choi, A1
Park, CB1
Ren, S1
Sanyal, AJ1
Kwan, HY1
Niu, X1
Dai, W1
Tong, T1
Chao, X1
Su, T1
Chan, CL1
Lee, KC1
Fu, X1
Yi, H1
Tse, AK1
Fong, WF1
Pan, SY1
Lu, A1
Yu, ZL1
Pilar Valdecantos, M1
Prieto-Hontoria, PL1
Módol, T1
Santamaría, B1
Weber, M1
Cuadrado, A1
Alfredo Martínez, J1
Chong, LW1
Hsu, YC1
Lee, TF1
Lin, Y1
Chiu, YT1
Yang, KC1
Wu, JC1
Huang, YT1
Hur, W1
Kim, SW1
Kim, JH2
Bae, SH1
Kim, M1
Hwang, D1
Kim, YS1
Park, T1
Um, SJ1
Song, BJ1
Yoon, SK1
Ganji, SH1
Kashyap, ML1
Kamanna, VS1
Inafuku, M1
Matsuzaki, G1
Oku, H1
Sharifnia, T1
Antoun, J1
Verriere, TG1
Suarez, G1
Wattacheril, J1
Wilson, KT1
Peek, RM1
Abumrad, NN1
Flynn, CR1
Xiao, J1
Xing, F1
Leung, TM1
Liong, EC1
Tipoe, GL1
Afonso, MB1
Rodrigues, PM1
Carvalho, T1
Caridade, M1
Borralho, P1
Cortez-Pinto, H1
Castro, RE1
Rodrigues, CM1
Shan, W2
Zeng, W2
Li, M1
Qi, Y1
Wang, W1
Dai, L1
Kaczorowski, D1
Xia, P1
Nishio, N1
Isobe, K1
Jung, TW1
Hong, HC1
Hwang, HJ1
Yoo, HJ1
Baik, SH1
Choi, KM1
Rein-Fischboeck, L1
Krautbauer, S1
Eisinger, K1
Pohl, R1
Meier, EM1
Weiss, TS2
Buechler, C1
Henkel, AS1
LeCuyer, BE1
Schipma, MJ1
Anderson, KA1
Green, RM1
Peng, J1
Martínez, L1
Torres, S1
Baulies, A1
Alarcón-Vila, C1
Elena, M1
Fabriàs, G1
Casas, J1
Caballeria, J1
Lee, HJ1
Yeon, JE1
Ko, EJ1
Yoon, EL1
Suh, SJ1
Kang, K1
Kim, HR1
Kang, SH1
Yoo, YJ1
Je, J1
Lee, BJ1
Seo, YS1
Yim, HJ1
Byun, KS1
Moravcová, A1
Červinková, Z1
Kučera, O1
Mezera, V1
Rychtrmoc, D1
Lotková, H1
Hirsova, P2
Ibrahim, SH2
Krishnan, A1
Verma, VK1
Bronk, SF2
Werneburg, NW1
Charlton, MR1
Shah, VH1
Gores, GJ1
Siculella, L1
Tocci, R1
Rochira, A1
Testini, M1
Gnoni, A1
Damiano, F1
Schattenberg, JM1
Lee, MS1
Sui, YH1
Luo, WJ1
Xu, QY1
Hua, J1
Bashiri, A1
Nesan, D1
Tavallaee, G1
Sue-Chue-Lam, I1
Chien, K1
Maguire, GF1
Naples, M1
Magomedova, L1
Adeli, K1
Cummins, CL1
Ng, DS1
Lim, A1
Sinha, RA1
Singh, BK1
Ghosh, S1
Lim, KH1
Chow, PK1
Woon, ECY1
Yen, PM1
Di Mauro, S1
Ragusa, M1
Urbano, F1
Filippello, A1
Di Pino, A1
Scamporrino, A1
Pulvirenti, A1
Ferro, A1
Rabuazzo, AM1
Purrello, M1
Purrello, F1
Piro, S1
Ai, DM1
Cao, ZY1
Pan, HP1
Nishio, T1
Taura, K1
Iwaisako, K1
Koyama, Y1
Tanabe, K1
Yamamoto, G1
Okuda, Y1
Ikeno, Y1
Yoshino, K1
Kasai, Y1
Okuno, M1
Seo, S1
Sakurai, T1
Asagiri, M1
Hatano, E1
Uemoto, S1
Amirkalali, B1
Sohrabi, MR1
Esrafily, A1
Jalali, M1
Gholami, A1
Hosseinzadeh, P1
Keyvani, H1
Shidfar, F1
Zamani, F1
Tomita, K1
Kabashima, A1
Freeman, BL1
Takahara, I1
Tabuchi, M1
Matsuda, K1
Kanda, Y1
Ohnita, K1
Takeshima, F1
Sakai, Y1
Eguchi, S1
Nakashima, M1
Dong, L1
Bai, J1
Gentile, CL1
Nivala, AM1
Gonzales, JC1
Pfaffenbach, KT1
Wei, Y1
Jiang, H1
Orlicky, DJ1
Petersen, DR1
Pagliassotti, MJ1
Maclean, KN1
Schnabl, B1
Czech, B1
Valletta, D1
Kirovski, G1
Hellerbrand, C1
Petit, JM1
Guiu, B1
Duvillard, L1
Jooste, V1
Brindisi, MC1
Athias, A1
Bouillet, B1
Habchi, M1
Cottet, V1
Gambert, P1
Hillon, P1
Cercueil, JP1
Verges, B1
Dai, DL1
Yu, HH1
Cheng, WH1
Chavez-Tapia, NC1
Rosso, N1
Tiribelli, C1
Ou, HY1
Wu, HT1
Hung, HC1
Yang, YC1
Wu, JS1
Chang, CJ1
Matsuzaka, T1
Atsumi, A1
Matsumori, R1
Nie, T1
Shinozaki, H1
Suzuki-Kemuriyama, N1
Kuba, M1
Nakagawa, Y1
Ishii, K1
Shimada, M1
Kobayashi, K1
Yatoh, S1
Takahashi, A1
Takekoshi, K1
Sone, H1
Yahagi, N1
Suzuki, H1
Murata, S1
Nakamuta, M1
Yamada, N1
Shimano, H1
Miura, K1
van Rooijen, N1
Brenner, DA1
Ohnishi, H1
Seki, E1
Titov, VN1
Ivanova, KV1
Malyshev, PP1
Kaba, SI1
Shiriaeva, IuK1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Medium-term Effects of a Portfolio Diet on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients[NCT03380416]49 participants (Actual)Interventional2017-04-04Completed
Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health[NCT02706262]180 participants (Anticipated)Interventional2016-02-29Recruiting
Effect of Dietary Macronutrient Composition on Liver Substrate Metabolism[NCT01371396]24 participants (Actual)Interventional2007-09-01Completed
Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis: A Multi-center, Randomized, Double Blind, Placebo-controlled Trial. The STATLiver Trial[NCT04072601]Phase 478 participants (Actual)Interventional2019-11-08Terminated (stopped due to Study part one completed)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

5 trials available for palmitic acid and Non-alcoholic Fatty Liver Disease

ArticleYear
Reduction of De Novo Lipogenesis Mediates Beneficial Effects of Isoenergetic Diets on Fatty Liver: Mechanistic Insights from the MEDEA Randomized Clinical Trial.
    Nutrients, 2022, May-23, Volume: 14, Issue:10

    Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus, Type 2; Diet; Humans; Lipogenesis; Non-alcoholic Fatty Liv

2022
A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease.
    Journal of cellular and molecular medicine, 2022, Volume: 26, Issue:14

    Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Humans; Hydrogen; Liver; Mice; Mice, I

2022
Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
    Lipids in health and disease, 2019, Oct-21, Volume: 18, Issue:1

    Topics: Adult; Animals; Autophagy; Carnitine O-Palmitoyltransferase; Case-Control Studies; Ceramides; Diet,

2019
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
    The Journal of clinical investigation, 2020, 03-02, Volume: 130, Issue:3

    Topics: Adult; Blood Glucose; Female; Humans; Insulin; Insulin Resistance; Lipogenesis; Liver; Male; Non-alc

2020
Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.
    The American journal of clinical nutrition, 2015, Volume: 101, Issue:1

    Topics: Adiposity; Adult; Algorithms; Biomarkers; Body Mass Index; Cross-Sectional Studies; Deuterium Oxide;

2015

Other Studies

158 other studies available for palmitic acid and Non-alcoholic Fatty Liver Disease

ArticleYear
Intermittent hypoxia aggravates non-alcoholic fatty liver disease via RIPK3-dependent necroptosis-modulated Nrf2/NFκB signaling pathway.
    Life sciences, 2021, Nov-15, Volume: 285

    Topics: Animals; Cell Line; Hepatocytes; Humans; Hydroquinones; Hypoxia; Male; Mice; Mice, Inbred Strains; N

2021
Establishment of an Adult Medaka Fatty Liver Model by Administration of a Gubra-Amylin-Nonalcoholic Steatohepatitis Diet Containing High Levels of Palmitic Acid and Fructose.
    International journal of molecular sciences, 2021, Sep-14, Volume: 22, Issue:18

    Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Female; Fenofibrate; Fructose; Gene Ex

2021
Carnosol alleviates nonalcoholic fatty liver disease by inhibiting mitochondrial dysfunction and apoptosis through targeting of PRDX3.
    Toxicology and applied pharmacology, 2021, 12-01, Volume: 432

    Topics: Abietanes; Animals; Antioxidants; Apoptosis; Cell Line; Diet, High-Fat; Disease Models, Animal; Enzy

2021
Network Pharmacology Exploration Reveals Anti-Apoptosis as a Common Therapeutic Mechanism for Non-Alcoholic Fatty Liver Disease Treated with Blueberry Leaf Polyphenols.
    Nutrients, 2021, Nov-13, Volume: 13, Issue:11

    Topics: Apoptosis; Blueberry Plants; Caspase 3; Gene Ontology; Hep G2 Cells; Humans; Lipid Metabolism; Netwo

2021
Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2.
    Cells, 2021, 11-25, Volume: 10, Issue:12

    Topics: Animals; Binding, Competitive; Blood Circulation; Diet, High-Fat; Fibronectins; Hepatocytes; Inflamm

2021
Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling.
    International immunopharmacology, 2022, Volume: 104

    Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Antioxidants; Cell Line; Cytokines

2022
Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis.
    Nutrients, 2021, Dec-24, Volume: 14, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Ceramides; Diet, High-Fat; Hep G2 Cells; Humans;

2021
Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway.
    Endocrinology and metabolism (Seoul, Korea), 2022, Volume: 37, Issue:1

    Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Immunoglobulin Fc Fragments; Non-alcoholi

2022
Luteoloside Ameliorates Palmitic Acid-Induced in Vitro Model of Non-alcoholic Fatty Liver Disease via Activating STAT3-Triggered Hepatocyte Regeneration.
    Folia biologica, 2021, Volume: 67, Issue:3

    Topics: Glucosides; Hepatocytes; Humans; Liver; Luteolin; Non-alcoholic Fatty Liver Disease; Palmitic Acid;

2021
Gryllus bimaculatus De Geer hydrolysates alleviate lipid accumulation, inflammation, and endoplasmic reticulum stress in palmitic acid-treated human hepatoma G2 cells.
    Journal of ethnopharmacology, 2022, Jun-12, Volume: 291

    Topics: Carcinoma, Hepatocellular; Endoplasmic Reticulum Stress; Hep G2 Cells; Hepatocytes; Humans; Inflamma

2022
Hepatocyte Proteome Alterations Induced by Individual and Combinations of Common Free Fatty Acids.
    International journal of molecular sciences, 2022, Mar-20, Volume: 23, Issue:6

    Topics: Fatty Acids; Fatty Acids, Nonesterified; Hepatocytes; Humans; Non-alcoholic Fatty Liver Disease; Ole

2022
DDX17 protects hepatocytes against oleic acid/palmitic acid-induced lipid accumulation.
    Biochemical and biophysical research communications, 2022, 07-05, Volume: 612

    Topics: Animals; Carcinoma, Hepatocellular; DEAD-box RNA Helicases; Hep G2 Cells; Hepatocytes; Humans; Lipid

2022
PREX1 depletion ameliorates high-fat diet-induced non-alcoholic fatty liver disease in mice and mitigates palmitic acid-induced hepatocellular injury via suppressing the NF-κB signaling pathway.
    Toxicology and applied pharmacology, 2022, 08-01, Volume: 448

    Topics: Animals; Carcinoma, Hepatocellular; Diet, High-Fat; Guanine Nucleotide Exchange Factors; Inflammatio

2022
Ptpn1 deletion protects oval cells against lipoapoptosis by favoring lipid droplet formation and dynamics.
    Cell death and differentiation, 2022, Volume: 29, Issue:12

    Topics: Animals; Gene Deletion; Hepatocytes; Lipid Droplets; Mice; Non-alcoholic Fatty Liver Disease; Palmit

2022
RNA adenosine deaminase (ADAR1) alleviates high-fat diet-induced nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome.
    Laboratory investigation; a journal of technical methods and pathology, 2022, Volume: 102, Issue:10

    Topics: Adenosine Deaminase; Animals; Diet, High-Fat; Inflammasomes; Lipopolysaccharides; Liver; Mice; Mice,

2022
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways.
    Clinical and molecular hepatology, 2022, Volume: 28, Issue:4

    Topics: Animals; Antioxidants; Auranofin; Collagen; Endothelin-1; Fibronectins; Humans; Liver; Liver Cirrhos

2022
Indole-3-acetic acid improves the hepatic mitochondrial respiration defects by PGC1a up-regulation.
    Cellular signalling, 2022, Volume: 99

    Topics: Glucose; Humans; Indoleacetic Acids; Liver; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Peroxi

2022
Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate experimental non-alcoholic steatohepatitis via Nrf2/NQO-1 pathway.
    Free radical biology & medicine, 2022, 11-01, Volume: 192

    Topics: Animals; Antioxidants; Cholesterol; Culture Media, Conditioned; Cytochrome P-450 CYP2E1; Exosomes; F

2022
Exercise inhibits JNK pathway activation and lipotoxicity
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Animals; Macrophage Migration-Inhibitory Factors; MAP Kinase Signaling System; Mice; Mitogen-Activat

2022
Mapping Proteome and Lipidome Changes in Early-Onset Non-Alcoholic Fatty Liver Disease Using Hepatic 3D Spheroids.
    Cells, 2022, 10-13, Volume: 11, Issue:20

    Topics: Adenosine Triphosphate; Cadherins; Ceramides; Epithelial-Mesenchymal Transition; Hep G2 Cells; Human

2022
Isosilybin regulates lipogenesis and fatty acid oxidation via the AMPK/SREBP-1c/PPARα pathway.
    Chemico-biological interactions, 2022, Dec-01, Volume: 368

    Topics: Adenylate Kinase; AMP-Activated Protein Kinases; Fatty Acids; Fatty Acids, Nonesterified; Hep G2 Cel

2022
CircLDLR acts as a sponge for miR-667-5p to regulate SIRT1 expression in non-alcoholic fatty liver disease.
    Lipids in health and disease, 2022, Nov-29, Volume: 21, Issue:1

    Topics: Animals; In Situ Hybridization, Fluorescence; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; MicroR

2022
CircLDLR acts as a sponge for miR-667-5p to regulate SIRT1 expression in non-alcoholic fatty liver disease.
    Lipids in health and disease, 2022, Nov-29, Volume: 21, Issue:1

    Topics: Animals; In Situ Hybridization, Fluorescence; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; MicroR

2022
CircLDLR acts as a sponge for miR-667-5p to regulate SIRT1 expression in non-alcoholic fatty liver disease.
    Lipids in health and disease, 2022, Nov-29, Volume: 21, Issue:1

    Topics: Animals; In Situ Hybridization, Fluorescence; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; MicroR

2022
CircLDLR acts as a sponge for miR-667-5p to regulate SIRT1 expression in non-alcoholic fatty liver disease.
    Lipids in health and disease, 2022, Nov-29, Volume: 21, Issue:1

    Topics: Animals; In Situ Hybridization, Fluorescence; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; MicroR

2022
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro.
    Molecular and cellular biochemistry, 2023, Volume: 478, Issue:8

    Topics: Carcinoma, Hepatocellular; Flavonoids; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; P

2023
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro.
    Molecular and cellular biochemistry, 2023, Volume: 478, Issue:8

    Topics: Carcinoma, Hepatocellular; Flavonoids; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; P

2023
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro.
    Molecular and cellular biochemistry, 2023, Volume: 478, Issue:8

    Topics: Carcinoma, Hepatocellular; Flavonoids; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; P

2023
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro.
    Molecular and cellular biochemistry, 2023, Volume: 478, Issue:8

    Topics: Carcinoma, Hepatocellular; Flavonoids; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; P

2023
Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model.
    Journal of visualized experiments : JoVE, 2022, 12-02, Issue:190

    Topics: Liver; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Platycodon; Reactive Oxygen Species; Seques

2022
A small-molecule JNK inhibitor JM-2 attenuates high-fat diet-induced non-alcoholic fatty liver disease in mice.
    International immunopharmacology, 2023, Volume: 115

    Topics: Animals; Diet, High-Fat; Fibrosis; Hepatocytes; Inflammation; Liver; Mice; Mice, Inbred C57BL; Non-a

2023
Long-chain saturated fatty acids and its interaction with insulin resistance and the risk of nonalcoholic fatty liver disease in type 2 diabetes in Chinese.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Diabetes Mellitus, Type 2; East Asian People; Fatty Acids; Humans; Insulin Resistance; Myristic Acid

2022
Metabolomic analysis shows dysregulation in amino acid and NAD+ metabolism in palmitate treated hepatocytes and plasma of non-alcoholic fatty liver disease spectrum.
    Biochemical and biophysical research communications, 2023, 02-05, Volume: 643

    Topics: Amino Acids; Hepatocytes; Humans; Kynurenine; Liver; Liver Cirrhosis; NAD; Non-alcoholic Fatty Liver

2023
Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome.
    European journal of pharmacology, 2023, Mar-05, Volume: 942

    Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Inflammasomes; Inflammation; Lipid Metabolis

2023
FGF1 ameliorates obesity-associated hepatic steatosis by reversing IGFBP2 hypermethylation.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2023, Volume: 37, Issue:4

    Topics: Animals; Diet, High-Fat; Disease Models, Animal; Epigenesis, Genetic; Fibroblast Growth Factor 1; In

2023
Uncarboxylated Osteocalcin Decreases SCD1 by Activating AMPK to Alleviate Hepatocyte Lipid Accumulation.
    Molecules (Basel, Switzerland), 2023, Mar-31, Volume: 28, Issue:7

    Topics: AMP-Activated Protein Kinases; Animals; Coenzyme A; Hep G2 Cells; Hepatocytes; Humans; Lipid Metabol

2023
The Presence of Periodontitis Exacerbates Non-Alcoholic Fatty Liver Disease via Sphingolipid Metabolism-Associated Insulin Resistance and Hepatic Inflammation in Mice with Metabolic Syndrome.
    International journal of molecular sciences, 2023, May-05, Volume: 24, Issue:9

    Topics: Animals; Ceramides; Diet, High-Fat; Imipramine; Inflammation; Insulin Resistance; Lipopolysaccharide

2023
PKC-δ-dependent mitochondrial ROS attenuation is involved as 9-OAHSA combats lipoapotosis in rat hepatocytes induced by palmitic acid and in Syrian hamsters induced by high-fat high-cholesterol high-fructose diet.
    Toxicology and applied pharmacology, 2023, 07-01, Volume: 470

    Topics: Animals; Cholesterol; Cricetinae; Diet, High-Fat; Fatty Acids; Fructose; Hepatocytes; Mesocricetus;

2023
Oleic acid improves hepatic lipotoxicity injury by alleviating autophagy dysfunction.
    Experimental cell research, 2023, Aug-15, Volume: 429, Issue:2

    Topics: Animals; Autophagy; Diet, High-Fat; Endoplasmic Reticulum Stress; Hepatocytes; Humans; Liver; Mice;

2023
A network pharmacology-based approach to explore the effect of dihydromyricetin on non-alcoholic fatty liver rats via regulating PPARG and CASP3.
    Molecular and cellular probes, 2023, Volume: 71

    Topics: Animals; Caspase 3; Lipid Metabolism; Liver; Network Pharmacology; Non-alcoholic Fatty Liver Disease

2023
CXCL5 promotes lipotoxicity of hepatocytes through upregulating NLRP3/Caspase-1/IL-1β signaling in Kupffer cells and exacerbates nonalcoholic steatohepatitis in mice.
    International immunopharmacology, 2023, Volume: 123

    Topics: Animals; Caspase 1; Diabetes Mellitus, Type 2; Hepatocytes; Inflammasomes; Interleukin-1beta; Kupffe

2023
The Different Mechanisms of Lipid Accumulation in Hepatocytes Induced by Oleic Acid/Palmitic Acid and High-Fat Diet.
    Molecules (Basel, Switzerland), 2023, Sep-20, Volume: 28, Issue:18

    Topics: Animals; CD36 Antigens; Diet, High-Fat; Disease Models, Animal; Fatty Acids, Nonesterified; Hepatocy

2023
Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway.
    Drug design, development and therapy, 2023, Volume: 17

    Topics: AMP-Activated Protein Kinases; Animals; Hypercholesterolemia; Lipid Metabolism; Liver; Non-alcoholic

2023
(+)-Lipoic Acid Reduces Lipotoxicity and Regulates Mitochondrial Homeostasis and Energy Balance in an In Vitro Model of Liver Steatosis.
    International journal of molecular sciences, 2023, Sep-23, Volume: 24, Issue:19

    Topics: Energy Metabolism; Hepatocytes; Humans; Liver; Mitochondria; Non-alcoholic Fatty Liver Disease; Olei

2023
Erchen decoction alleviates the progression of NAFLD by inhibiting lipid accumulation and iron overload through Caveolin-1 signaling.
    Journal of ethnopharmacology, 2024, Jan-30, Volume: 319, Issue:Pt 3

    Topics: Animals; Caveolin 1; Diet, High-Fat; Iron; Iron Overload; Lipid Metabolism; Liver; Mice; Mice, Inbre

2024
Comparison of effects of HucMSCs, exosomes, and conditioned medium on NASH.
    Scientific reports, 2023, 10-27, Volume: 13, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Choline; Collagen; Culture Media, Conditioned; Exosomes; Hum

2023
Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
    Chemico-biological interactions, 2019, Sep-25, Volume: 311

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cell Line; Diet, High-Fat;

2019
Carbon monoxide releasing molecule-A1 improves nonalcoholic steatohepatitis via Nrf2 activation mediated improvement in oxidative stress and mitochondrial function.
    Redox biology, 2020, Volume: 28

    Topics: Animals; Boranes; Carbonates; Cell Survival; Diet, High-Fat; Disease Models, Animal; Gene Expression

2020
Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
    BMC complementary and alternative medicine, 2019, Sep-13, Volume: 19, Issue:1

    Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Carnitine O-Acetyltransferase; Cell Line; Dio

2019
Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
    World journal of gastroenterology, 2019, Sep-14, Volume: 25, Issue:34

    Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Diet, High-Fat; Disease Models, Animal; Down-Regu

2019
Exogenous Hydrogen Sulfide Alleviates-Induced Intracellular Inflammation in HepG2 Cells.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2020, Volume: 128, Issue:3

    Topics: Cytokines; Hep G2 Cells; Hepatocytes; Humans; Hydrogen Sulfide; Inflammasomes; Inflammation; NLR Fam

2020
Sodium fluorocitrate having inhibitory effect on fatty acid uptake ameliorates high fat diet-induced non-alcoholic fatty liver disease in C57BL/6J mice.
    Scientific reports, 2019, 11-28, Volume: 9, Issue:1

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Citrates; Diet, High-Fat; Hep G2 Cells;

2019
Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes.
    EBioMedicine, 2020, Volume: 53

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Cells, Cultured; Ceramides; DEAD-box RNA Helicases; E

2020
Ginsenoside Rg2 Ameliorates High-Fat Diet-Induced Metabolic Disease through SIRT1.
    Journal of agricultural and food chemistry, 2020, Apr-08, Volume: 68, Issue:14

    Topics: Animals; Antioxidants; Apoptosis; Blood Glucose; Body Weight; Diet, High-Fat; Gene Expression Regula

2020
MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcohol-associated fatty liver and steatohepatitis.
    Journal of hepatology, 2020, Volume: 73, Issue:3

    Topics: Animals; Apoptosis; Autophagosomes; Autophagy; Cell Line, Transformed; Cell Membrane; Diet, Western;

2020
Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signalling pathways.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:9

    Topics: AMP-Activated Protein Kinases; Animals; Gene Expression Regulation; Hep G2 Cells; Humans; Inflammati

2020
Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes.
    PloS one, 2020, Volume: 15, Issue:5

    Topics: Animals; Berberine; Cytokines; Endoplasmic Reticulum Stress; Hepatocytes; Inflammation; Lipopolysacc

2020
Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes.
    Nutrients, 2020, May-20, Volume: 12, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Caspase 3; Caspase 7; Gallic Acid; Gene Expressio

2020
Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease.
    Life sciences, 2020, Sep-15, Volume: 257

    Topics: Alkaloids; Animals; Body Weight; Diet, High-Fat; Gene Knockdown Techniques; Hep G2 Cells; Humans; In

2020
Expression of Notch family is altered in non‑alcoholic fatty liver disease.
    Molecular medicine reports, 2020, Volume: 22, Issue:3

    Topics: Animals; Cell Line; Cell Movement; Cell Proliferation; Diet; Disease Models, Animal; Gene Expression

2020
miR-3666 inhibits development of hepatic steatosis by negatively regulating PPARγ.
    Biochimica et biophysica acta. Molecular and cell biology of lipids, 2020, Volume: 1865, Issue:10

    Topics: 3' Untranslated Regions; Animals; Fatty Liver; Gene Expression Regulation; Hep G2 Cells; Humans; Liv

2020
Amelioration of the Lipogenesis, Oxidative Stress and Apoptosis of Hepatocytes by a Novel Proteoglycan from Ganoderma lucidum.
    Biological & pharmaceutical bulletin, 2020, Oct-01, Volume: 43, Issue:10

    Topics: Antioxidants; Apoptosis; Fungal Polysaccharides; Hep G2 Cells; Hepatocytes; Humans; Lipogenesis; Non

2020
LRRK2 Regulates CPT1A to Promote β-Oxidation in HepG2 Cells.
    Molecules (Basel, Switzerland), 2020, Sep-09, Volume: 25, Issue:18

    Topics: Animals; Carnitine O-Palmitoyltransferase; Cell Nucleus; Cytokines; Diet, High-Fat; Hep G2 Cells; Hu

2020
New Perspectives of S-Adenosylmethionine (SAMe) Applications to Attenuate Fatty Acid-Induced Steatosis and Oxidative Stress in Hepatic and Endothelial Cells.
    Molecules (Basel, Switzerland), 2020, Sep-15, Volume: 25, Issue:18

    Topics: Animals; Cell Line, Tumor; Cell Movement; Endothelial Cells; Hepatocytes; Malondialdehyde; Nitric Ox

2020
Coniferaldehyde ameliorates the lipid and glucose metabolism in palmitic acid-induced HepG2 cells via the LKB1/AMPK signaling pathway.
    Journal of food science, 2020, Volume: 85, Issue:11

    Topics: Acrolein; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Glucose; Hep G2 Cells

2020
Acute Elevated Resistin Exacerbates Mitochondrial Damage and Aggravates Liver Steatosis Through AMPK/PGC-1α Signaling Pathway in Male NAFLD Mice.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2021, Volume: 53, Issue:2

    Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Gene Expression Regulation; Hep G2 Cells; Hu

2021
Src-mediated Tyr353 phosphorylation of IP3R1 promotes its stability and causes apoptosis in palmitic acid-treated hepatocytes.
    Experimental cell research, 2021, 02-15, Volume: 399, Issue:2

    Topics: Apoptosis; Cells, Cultured; Hep G2 Cells; Hepatocytes; Humans; Indoles; Inositol 1,4,5-Trisphosphate

2021
Mesenchymal stem cell-conditioned medium improved mitochondrial function and alleviated inflammation and apoptosis in non-alcoholic fatty liver disease by regulating SIRT1.
    Biochemical and biophysical research communications, 2021, 03-26, Volume: 546

    Topics: Animals; Apoptosis; Cell Line; Cells, Cultured; Culture Media, Conditioned; Diabetes Mellitus, Type

2021
Silibinin improves nonalcoholic fatty liver by regulating the expression of miR‑122: An
    Molecular medicine reports, 2021, Volume: 23, Issue:5

    Topics: Acetyl-CoA Carboxylase; Animals; Fatty Acid Synthases; Gene Expression Regulation; Hep G2 Cells; Hum

2021
Role of HO-1 against Saturated Fatty Acid-Induced Oxidative Stress in Hepatocytes.
    Nutrients, 2021, Mar-19, Volume: 13, Issue:3

    Topics: Animals; Diet, High-Fat; Endoplasmic Reticulum Stress; Fatty Acids; Gene Expression; Heme Oxygenase-

2021
Lipotoxicity reduces DDX58/Rig-1 expression and activity leading to impaired autophagy and cell death.
    Autophagy, 2022, Volume: 18, Issue:1

    Topics: Animals; Autophagy; Cell Death; Inflammation; Mice; Non-alcoholic Fatty Liver Disease; Palmitic Acid

2022
Exploratory Data Analysis of Cell and Mitochondrial High-Fat, High-Sugar Toxicity on Human HepG2 Cells.
    Nutrients, 2021, May-19, Volume: 13, Issue:5

    Topics: Carcinoma, Hepatocellular; Cell Death; Data Analysis; Diet, High-Fat; Dietary Carbohydrates; Fatty A

2021
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium.
    Journal of visualized experiments : JoVE, 2021, 05-18, Issue:171

    Topics: Cell Culture Techniques; Culture Media, Conditioned; Hep G2 Cells; Hepatocytes; Humans; Lipid Metabo

2021
Impaired Ca
    American journal of physiology. Cell physiology, 2021, 07-01, Volume: 321, Issue:1

    Topics: Alstrom Syndrome; Animals; Blood Glucose; Calcium; Calcium Signaling; Diabetes Mellitus, Type 2; Dis

2021
The mechanism of increased intestinal palmitic acid absorption and its impact on hepatic stellate cell activation in nonalcoholic steatohepatitis.
    Scientific reports, 2021, 06-28, Volume: 11, Issue:1

    Topics: Animals; Chylomicrons; Hepatic Stellate Cells; Humans; Intestinal Absorption; Liver; Liver Cirrhosis

2021
γ-Linolenic Acid Prevents Lipid Metabolism Disorder in Palmitic Acid-Treated Alpha Mouse Liver-12 Cells by Balancing Autophagy and Apoptosis via the LKB1-AMPK-mTOR Pathway.
    Journal of agricultural and food chemistry, 2021, Jul-28, Volume: 69, Issue:29

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; gamma-Linolenic Acid; Lipid Metabolism

2021
[Exendin-4 promotes autophagy to relieve lipid deposition in a NAFLD cell model by activating AKT/mTOR signaling pathway].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2021, Jul-20, Volume: 41, Issue:7

    Topics: Autophagy; Exenatide; Humans; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Proto-Oncogene Prote

2021
Palmitic acid elicits hepatic stellate cell activation through inflammasomes and hedgehog signaling.
    Life sciences, 2017, May-01, Volume: 176

    Topics: Animals; Hedgehog Proteins; Hepatic Stellate Cells; Humans; Inflammasomes; Male; NLR Family, Pyrin D

2017
O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress.
    Journal of hepatology, 2017, Volume: 67, Issue:2

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum Stre

2017
O-GlcNAcylation: Undesired tripmate but an opportunity for treatment in NAFLD-HCC.
    Journal of hepatology, 2017, Volume: 67, Issue:2

    Topics: Animals; Endoplasmic Reticulum Stress; Glycosylation; Liver Neoplasms; N-Acetylglucosaminyltransfera

2017
Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
    Oncotarget, 2017, Jun-06, Volume: 8, Issue:23

    Topics: Adult; Animals; Carrier Proteins; Cells, Cultured; Diet, High-Fat; Disease Progression; Fatty Liver;

2017
Nonalcoholic fatty liver disease impairs the cytochrome P-450-dependent metabolism of α-tocopherol (vitamin E).
    The Journal of nutritional biochemistry, 2017, Volume: 47

    Topics: alpha-Tocopherol; Animals; Cytochrome P450 Family 4; Diet, Carbohydrate Loading; Diet, High-Fat; Die

2017
Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.
    World journal of gastroenterology, 2017, Jun-21, Volume: 23, Issue:23

    Topics: Acetamides; Animals; Apoptosis; Biomarkers, Tumor; Diet, High-Fat; Fibrosis; Gene Expression Regulat

2017
NLRP3 Deletion Inhibits the Non-alcoholic Steatohepatitis Development and Inflammation in Kupffer Cells Induced by Palmitic Acid.
    Inflammation, 2017, Volume: 40, Issue:6

    Topics: Animals; Inflammation; Interleukin-18; Interleukin-1beta; Kupffer Cells; Liver; Mice; NLR Family, Py

2017
The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells.
    Canadian journal of physiology and pharmacology, 2017, Volume: 95, Issue:12

    Topics: Cell Survival; Cytoprotection; Dose-Response Relationship, Drug; Hep G2 Cells; Hepatocytes; Humans;

2017
Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis.
    Scientific reports, 2017, 08-22, Volume: 7, Issue:1

    Topics: Animals; Autophagy; Cell Line; Diet, High-Fat; Disease Models, Animal; Humans; Insulin; Leupeptins;

2017
Hepatitis C Virus Infection Increases c-Jun N-Terminal Kinase (JNK) Phosphorylation and Accentuates Hepatocyte Lipoapoptosis.
    Medical science monitor : international medical journal of experimental and clinical research, 2017, Sep-21, Volume: 23

    Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Cell Li

2017
MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
    Biochimica et biophysica acta. Molecular basis of disease, 2017, Volume: 1863, Issue:12

    Topics: Animals; Diet, High-Fat; Down-Regulation; Gene Silencing; HEK293 Cells; Hep G2 Cells; Hepatocytes; H

2017
PKCδ silencing alleviates saturated fatty acid induced ER stress by enhancing SERCA activity.
    Bioscience reports, 2017, Dec-22, Volume: 37, Issue:6

    Topics: Biomarkers; Calcium; Cell Line; Endoplasmic Reticulum Stress; Fatty Acids; Hepatocytes; Homeostasis;

2017
Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease.
    Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:2

    Topics: Animals; Chalcones; Diet, High-Fat; Disease Progression; Gene Expression Regulation; Hep G2 Cells; H

2018
miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1.
    World journal of gastroenterology, 2017, Dec-14, Volume: 23, Issue:46

    Topics: Animals; Cell Line, Tumor; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Gene Knockdown T

2017
Alleviation of palmitic acid-induced endoplasmic reticulum stress by augmenter of liver regeneration through IP3R-controlled Ca
    Journal of cellular physiology, 2018, Volume: 233, Issue:8

    Topics: Calcium; Cell Line, Tumor; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Hep G2 Cells; Hepato

2018
Increased expression of sterol regulatory element binding protein‑2 alleviates autophagic dysfunction in NAFLD.
    International journal of molecular medicine, 2018, Volume: 41, Issue:4

    Topics: Autophagy; Hep G2 Cells; Hepatocytes; Humans; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Ster

2018
Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease.
    Clinical and experimental pharmacology & physiology, 2018, Volume: 45, Issue:8

    Topics: Adipokines; Animals; Cytokines; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Hep G2 Cell

2018
Heat shock protein 70 promotes lipogenesis in HepG2 cells.
    Lipids in health and disease, 2018, Apr-10, Volume: 17, Issue:1

    Topics: Animals; Diet, High-Fat; Enzymes; Gene Knockdown Techniques; Hep G2 Cells; HSP70 Heat-Shock Proteins

2018
Treatment of cigarette smoke extract and condensate differentially potentiates palmitic acid-induced lipotoxicity and steatohepatitis in vitro.
    Toxicology in vitro : an international journal published in association with BIBRA, 2018, Volume: 52

    Topics: Animals; Cells, Cultured; Coculture Techniques; Cytokines; Hepatocytes; Kupffer Cells; Lipopolysacch

2018
Saturated fatty acid combined with lipopolysaccharide stimulates a strong inflammatory response in hepatocytes in vivo and in vitro.
    American journal of physiology. Endocrinology and metabolism, 2018, 11-01, Volume: 315, Issue:5

    Topics: Animals; Diet, High-Fat; Fatty Acids; Hepatocytes; Inflammation; Interleukin-6; Lipopolysaccharides;

2018
Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress.
    Lipids in health and disease, 2018, Jul-17, Volume: 17, Issue:1

    Topics: Actins; Animals; CD36 Antigens; Cell Line; Desmin; Diet, High-Fat; Gene Expression Regulation; Hepat

2018
Cangju Qinggan Jiangzhi Decoction Reduces the Development of NonAlcoholic Steatohepatitis and Activation of Kupffer Cells.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 48, Issue:3

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Caspases; Cytokines; Diet, High-Fat; Dis

2018
Advanced Liver Fibrosis Is Independently Associated with Palmitic Acid and Insulin Levels in Patients with Non-Alcoholic Fatty Liver Disease.
    Nutrients, 2018, Oct-29, Volume: 10, Issue:11

    Topics: Acetyltransferases; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Delta-5 Fatty Acid Desa

2018
Stable Isotope-Labeled Lipidomics to Unravel the Heterogeneous Development Lipotoxicity.
    Molecules (Basel, Switzerland), 2018, Nov-02, Volume: 23, Issue:11

    Topics: Fatty Acids; Fatty Acids, Monounsaturated; Hep G2 Cells; Humans; Isotope Labeling; Lipid Metabolism;

2018
Matrine attenuates endoplasmic reticulum stress and mitochondrion dysfunction in nonalcoholic fatty liver disease by regulating SERCA pathway.
    Journal of translational medicine, 2018, 11-20, Volume: 16, Issue:1

    Topics: Alkaloids; Animals; Apoptosis; Body Weight; Calcium; Cytosol; Diet, High-Fat; Endoplasmic Reticulum

2018
Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease.
    BMC medical genomics, 2018, Dec-14, Volume: 11, Issue:1

    Topics: Carnitine O-Palmitoyltransferase; Cells, Cultured; Endoplasmic Reticulum Stress; Gene Expression Reg

2018
Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
    Biochemical and biophysical research communications, 2019, 01-22, Volume: 508, Issue:4

    Topics: 3' Untranslated Regions; Animals; Base Sequence; Cell Line; Hepatocytes; Humans; Lipid Metabolism; M

2019
Hepatocyte-Derived Lipotoxic Extracellular Vesicle Sphingosine 1-Phosphate Induces Macrophage Chemotaxis.
    Frontiers in immunology, 2018, Volume: 9

    Topics: Animals; Cell Line; Chemotaxis; Diet, Atherogenic; Diet, Carbohydrate Loading; Diet, High-Fat; Disea

2018
Cordycepin alleviates hepatic lipid accumulation by inducing protective autophagy via PKA/mTOR pathway.
    Biochemical and biophysical research communications, 2019, 08-27, Volume: 516, Issue:3

    Topics: Autophagy; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Deoxyadenosines; Hep G2 Cells; Human

2019
Metabolomic signatures in lipid-loaded HepaRGs reveal pathways involved in steatotic progression.
    Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:12

    Topics: Bile Acids and Salts; Diglycerides; Disease Progression; Fatty Liver; HEK293 Cells; Hep G2 Cells; Hu

2013
Saturated free fatty acid sodium palmitate-induced lipoapoptosis by targeting glycogen synthase kinase-3β activation in human liver cells.
    Digestive diseases and sciences, 2014, Volume: 59, Issue:2

    Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Shape; Endoplasmic Reticulum Stress; Enzyme A

2014
EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD.
    International journal of molecular sciences, 2013, Dec-12, Volume: 14, Issue:12

    Topics: Adenosine; Animals; Disease Models, Animal; Down-Regulation; Enhancer of Zeste Homolog 2 Protein; Fa

2013
Palmitic acid induces autophagy in hepatocytes via JNK2 activation.
    Acta pharmacologica Sinica, 2014, Volume: 35, Issue:4

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1;

2014
PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells.
    Human molecular genetics, 2014, Aug-01, Volume: 23, Issue:15

    Topics: Adult; Diterpenes; Female; Gene Expression Regulation; Hep G2 Cells; Hepatic Stellate Cells; Humans;

2014
Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD.
    Cell death & disease, 2014, Apr-17, Volume: 5

    Topics: Animals; Autophagy; Cell Line, Tumor; Demography; Diet, High-Fat; Endoplasmic Reticulum Chaperone Bi

2014
Overexpression of juxtaposed with another zinc finger gene 1 reduces proinflammatory cytokine release via inhibition of stress-activated protein kinases and nuclear factor-κB.
    The FEBS journal, 2014, Volume: 281, Issue:14

    Topics: Animals; Chemokine CCL2; Co-Repressor Proteins; Cytokines; Diet, High-Fat; DNA-Binding Proteins; Fat

2014
Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo.
    Journal of hepatology, 2014, Volume: 61, Issue:5

    Topics: Animals; Carrier Proteins; Cell Line; Diet, High-Fat; Disease Models, Animal; Hepatocytes; Humans; L

2014
Decreasing mitochondrial fission alleviates hepatic steatosis in a murine model of nonalcoholic fatty liver disease.
    American journal of physiology. Gastrointestinal and liver physiology, 2014, Sep-15, Volume: 307, Issue:6

    Topics: Animals; Cells, Cultured; Diet, High-Fat; Disease Models, Animal; Disease Progression; Energy Metabo

2014
PRMT3 regulates hepatic lipogenesis through direct interaction with LXRα.
    Diabetes, 2015, Volume: 64, Issue:1

    Topics: Aged; Animals; Diet, High-Fat; Female; Fibroblasts; Genes, Reporter; HEK293 Cells; Humans; Lipogenes

2015
Mmu-miR-615-3p regulates lipoapoptosis by inhibiting C/EBP homologous protein.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Binding Sites; Cell Line, Tumor; Cells,

2014
CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice.
    American journal of physiology. Endocrinology and metabolism, 2015, Jan-15, Volume: 308, Issue:2

    Topics: 8,11,14-Eicosatrienoic Acid; Alanine Transaminase; Animals; Aspartate Aminotransferases; Catalase; C

2015
Uncoupling protein 2 regulates palmitic acid-induced hepatoma cell autophagy.
    BioMed research international, 2014, Volume: 2014

    Topics: Apoptosis; Autophagy; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Gene Expression Regula

2014
In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in nonalcoholic steatohepatitis.
    Disease models & mechanisms, 2015, Volume: 8, Issue:2

    Topics: Adenosine Triphosphate; DNA, Mitochondrial; Fatty Acids; Gene Expression Regulation, Neoplastic; Gen

2015
Palmitate activation by fatty acid transport protein 4 as a model system for hepatocellular apoptosis and steatosis.
    Biochimica et biophysica acta, 2015, Volume: 1851, Issue:5

    Topics: Acyl Coenzyme A; Animals; Apoptosis; Cell Line, Tumor; Ceramides; Diet, High-Fat; Disease Models, An

2015
Sab (Sh3bp5) dependence of JNK mediated inhibition of mitochondrial respiration in palmitic acid induced hepatocyte lipotoxicity.
    Journal of hepatology, 2015, Volume: 62, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antioxidants; Apoptosis; Cell Line; Cells, Cultured;

2015
Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease.
    American journal of physiology. Gastrointestinal and liver physiology, 2015, May-01, Volume: 308, Issue:9

    Topics: Adult; Aged; Autophagy-Related Protein 7; Case-Control Studies; Cell Line, Tumor; Cytokine Receptor

2015
Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers.
    Scientific reports, 2015, Mar-13, Volume: 5

    Topics: Animals; Cyclooctanes; Diet, High-Fat; Disease Models, Animal; Fasting; Fatty Acid Synthases; Fatty

2015
Essential role of Nrf2 in the protective effect of lipoic acid against lipoapoptosis in hepatocytes.
    Free radical biology & medicine, 2015, Volume: 84

    Topics: Active Transport, Cell Nucleus; Animals; Antioxidant Response Elements; Antioxidants; Apoptosis; Cel

2015
Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    BMC gastroenterology, 2015, Feb-15, Volume: 15

    Topics: Actins; Animals; Choline; Collagen Type I; Culture Media, Conditioned; Diet; Fatty Acids, Monounsatu

2015
Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway.
    The international journal of biochemistry & cell biology, 2015, Volume: 64

    Topics: Adenylate Kinase; Animals; Base Sequence; Binding Sites; Calcium-Binding Proteins; Cytokines; Diet,

2015
Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.
    Metabolism: clinical and experimental, 2015, Volume: 64, Issue:9

    Topics: Diacylglycerol O-Acyltransferase; Hepatocytes; Humans; Hypolipidemic Agents; Interleukin-8; Lipid Me

2015
Intravenous Mycobacterium Bovis Bacillus Calmette-Guérin Ameliorates Nonalcoholic Fatty Liver Disease in Obese, Diabetic ob/ob Mice.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adiponectin; Adipose Tissue, White; Animals; BCG Vaccine; Gene Expression Regulation; Hep G2 Cells;

2015
Hepatic TLR4 signaling in obese NAFLD.
    American journal of physiology. Gastrointestinal and liver physiology, 2015, Aug-15, Volume: 309, Issue:4

    Topics: Adult; Cell Line; Cells, Cultured; Female; Hepatocytes; Humans; Interferon Regulatory Factor-3; Lipo

2015
Bee's honey attenuates non-alcoholic steatohepatitis-induced hepatic injury through the regulation of thioredoxin-interacting protein-NLRP3 inflammasome pathway.
    European journal of nutrition, 2016, Volume: 55, Issue:4

    Topics: Animals; Carrier Proteins; Cell Cycle Proteins; Cell Line; Diet, High-Fat; Down-Regulation; Female;

2016
Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
    Clinical science (London, England : 1979), 2015, Oct-01, Volume: 129, Issue:8

    Topics: Animals; Case-Control Studies; Cell Death; Choline Deficiency; Diet, High-Fat; Disease Models, Anima

2015
Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease.
    Cell death & disease, 2015, Jul-23, Volume: 6

    Topics: Abietanes; Animals; Antioxidants; Apoptosis; Caspase 3; Diet, High-Fat; Gene Expression Regulation;

2015
Sphingosine Kinase 1 Protects Hepatocytes from Lipotoxicity via Down-regulation of IRE1α Protein Expression.
    The Journal of biological chemistry, 2015, Sep-18, Volume: 290, Issue:38

    Topics: Animals; Cell Survival; DNA-Binding Proteins; Down-Regulation; Endoplasmic Reticulum Stress; Endorib

2015
GADD34-deficient mice develop obesity, nonalcoholic fatty liver disease, hepatic carcinoma and insulin resistance.
    Scientific reports, 2015, Aug-28, Volume: 5

    Topics: Adipogenesis; Aging; Animals; Body Weight; Carcinoma, Hepatocellular; CHO Cells; Cricetinae; Cricetu

2015
C1q/TNF-Related Protein 9 (CTRP9) attenuates hepatic steatosis via the autophagy-mediated inhibition of endoplasmic reticulum stress.
    Molecular and cellular endocrinology, 2015, Dec-05, Volume: 417

    Topics: Adiponectin; Animals; Autophagy; Disease Models, Animal; Endoplasmic Reticulum Stress; Gene Expressi

2015
Hepatic scavenger receptor BI is associated with type 2 diabetes but unrelated to human and murine non-alcoholic fatty liver disease.
    Biochemical and biophysical research communications, 2015, Nov-13, Volume: 467, Issue:2

    Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Animals; Chemokines; Cytokines; Diabetes Mellitus, Type

2015
Hepatocyte X-box binding protein 1 deficiency increases liver injury in mice fed a high-fat/sugar diet.
    American journal of physiology. Gastrointestinal and liver physiology, 2015, Dec-15, Volume: 309, Issue:12

    Topics: Alanine Transaminase; Animals; Apoptosis; Cell Line, Tumor; Collagen Type I; Collagen Type I, alpha

2015
Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease.
    Scientific reports, 2015, Nov-03, Volume: 5

    Topics: Animals; Benzofurans; Cytokines; Diet, High-Fat; Hep G2 Cells; HMGB1 Protein; Humans; Liver; Male; N

2015
Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis.
    Oncotarget, 2015, Dec-08, Volume: 6, Issue:39

    Topics: Animals; Anthracenes; Apoptosis; Ceramides; Cholesterol; Disease Models, Animal; Endoplasmic Reticul

2015
Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
    World journal of gastroenterology, 2015, Dec-07, Volume: 21, Issue:45

    Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Cytoprotection; Diet, High-Fat; Disease Models, An

2015
The effect of oleic and palmitic acid on induction of steatosis and cytotoxicity on rat hepatocytes in primary culture.
    Physiological research, 2015, Volume: 64, Issue:Suppl 5

    Topics: Albumins; Animals; Apoptosis; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Hepa

2015
Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.
    Gastroenterology, 2016, Volume: 150, Issue:4

    Topics: Animals; Caspases; Cell Line, Tumor; Extracellular Vesicles; HEK293 Cells; Hepatitis; Hepatocytes; H

2016
Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis.
    Biochimica et biophysica acta, 2016, Volume: 1861, Issue:5

    Topics: 5' Untranslated Regions; Binding Sites; Gene Expression Regulation; Hep G2 Cells; Hepatocytes; Heter

2016
Extracellular Vesicles as Messengers Between Hepatocytes and Macrophages in Nonalcoholic Steatohepatitis.
    Gastroenterology, 2016, Volume: 150, Issue:4

    Topics: Animals; Extracellular Vesicles; Hepatitis; Hepatocytes; Humans; Inflammation Mediators; Liver; Lyso

2016
Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation.
    World journal of gastroenterology, 2016, Feb-28, Volume: 22, Issue:8

    Topics: Animals; Caspase 1; Cells, Cultured; Diet, High-Fat; Disease Models, Animal; Docosahexaenoic Acids;

2016
Cellular cholesterol accumulation modulates high fat high sucrose (HFHS) diet-induced ER stress and hepatic inflammasome activation in the development of non-alcoholic steatohepatitis.
    Biochimica et biophysica acta, 2016, Volume: 1861, Issue:7

    Topics: Animals; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Endoplasmic Reticulum Stress;

2016
Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity.
    Biochemical and biophysical research communications, 2016, Oct-21, Volume: 479, Issue:3

    Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Apoptosis; Cell Survival; Ceramides; Endopla

2016
Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:12

    Topics: CD36 Antigens; Cell Survival; Ceramides; Coenzyme A Ligases; Computational Biology; Diglycerides; Ge

2016
Decreased MiR-155 Level in the Peripheral Blood of Non-Alcoholic Fatty Liver Disease Patients may Serve as a Biomarker and may Influence LXR Activity.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2016, Volume: 39, Issue:6

    Topics: Animals; Base Sequence; Biomarkers; Case-Control Studies; Cell Line; Diet, High-Fat; Female; Gene Si

2016
Hepatic vagus nerve regulates Kupffer cell activation via α7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis.
    Journal of gastroenterology, 2017, Volume: 52, Issue:8

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Chemokine CCL2; Chimera; Choline; Choline Deficien

2017
Association between Nicotinamide Phosphoribosyltransferase and de novo Lipogenesis in Nonalcoholic Fatty Liver Disease.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2017, Volume: 26, Issue:3

    Topics: Adipose Tissue; Adolescent; Adult; Aged; Biomarkers; Cross-Sectional Studies; Erythrocyte Membrane;

2017
Mixed Lineage Kinase 3 Mediates the Induction of CXCL10 by a STAT1-Dependent Mechanism During Hepatocyte Lipotoxicity.
    Journal of cellular biochemistry, 2017, Volume: 118, Issue:10

    Topics: Chemokine CXCL10; Hep G2 Cells; Hepatocytes; Humans; Lysophosphatidylcholines; MAP Kinase Kinase Kin

2017
Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cells, Cultured; Diet, H

2017
Effect of α-linolenic acid on endoplasmic reticulum stress-mediated apoptosis of palmitic acid lipotoxicity in primary rat hepatocytes.
    Lipids in health and disease, 2011, Jul-25, Volume: 10

    Topics: alpha-Linolenic Acid; Animals; Apoptosis; Cell Survival; Cells, Cultured; Drug Evaluation, Preclinic

2011
Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2011, Volume: 301, Issue:6

    Topics: Animals; Cell Death; Cell Line, Tumor; Chemical and Drug Induced Liver Injury; Diet; Endoplasmic Ret

2011
Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease.
    International journal of clinical and experimental pathology, 2011, Volume: 4, Issue:7

    Topics: Cells, Cultured; Fatty Liver; Hepatocytes; Humans; Lipid Metabolism; Liver; Non-alcoholic Fatty Live

2011
Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes.
    Clinical nutrition (Edinburgh, Scotland), 2012, Volume: 31, Issue:4

    Topics: Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Supplements; Erythro

2012
Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK/ATF4/CHOP signaling pathway.
    Molecular and cellular biochemistry, 2012, Volume: 364, Issue:1-2

    Topics: Activating Transcription Factor 4; Apoptosis; Cell Survival; eIF-2 Kinase; Endoplasmic Reticulum Str

2012
Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease.
    BMC gastroenterology, 2012, Mar-01, Volume: 12

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytokines; Dose-Response Relationship, Drug;

2012
Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance.
    Endocrinology, 2012, Volume: 153, Issue:7

    Topics: Aged; alpha-2-HS-Glycoprotein; Animals; Biomarkers; Diabetes Mellitus; Endoplasmic Reticulum; Fatty

2012
Elovl6 promotes nonalcoholic steatohepatitis.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:6

    Topics: Acetyltransferases; Analysis of Variance; Animals; Blood Glucose; Carrier Proteins; Cholesterol; Die

2012
Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:2

    Topics: Animals; Caspase 1; Fatty Liver; Hepatic Stellate Cells; Inflammasomes; Interleukin-1alpha; Interleu

2013
[The unity of pathogenesis of insulin resistance syndrome and non-alcoholic fatty disease of liver. The metabolic disorder of fatty acids and triglycerides].
    Klinicheskaia laboratornaia diagnostika, 2012, Issue:11

    Topics: Animals; Apoptosis; Fatty Liver; Hepatocytes; Insulin Resistance; Lipid Metabolism; Liver; Non-alcoh

2012